Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2005

Content (11 Articles)

Report

Evidence for a Tumour Suppressive Function of APRG1 in Breast Cancer

A.C.A. Leris, T.R. Roberts, W.G. Jiang, R.F. Newbold, K. Mokbel

Report

RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast

Celina G. Kleer, Kent A. Griffith, Michael S. Sabel, Gary Gallagher, Kenneth L. van Golen, Zhi-Fen Wu, Sofia D. Merajver

Clinical trial

Timely Withdrawal of G-CSF Reduces the Occurrence of Thrombocytopenia During Dose-dense Chemotherapy

J.N.H. Timmer-Bonte, P.H.M. de Mulder, P.G.M. Peer, L.V.A.M. Beex, V.C.G. Tjan-Heijnen

Clinical Trial

A Multicenter Randomized Clinical Trial Evaluating Interleukin-2 Activated Hematopoietic Stem Cell Transplantation and Post-transplant IL-2 for High Risk Breast Cancer Patients

Claudine Isaacs, Rebecca Slack, Edmund Gehan, Karen Ballen, Ralph Boccia, Ellen Areman, Ruthie Kramer, Daniel F. Hayes, Herbert Herscowitz, Marc Lippman

Report

The role of X-linked genes in breast cancer

Archana Thakur, Hiaming Xu, Yong Wang, Aliccia Bollig, Hector Biliran, Joshua D. Liao

Report

Incidence of Male Breast Cancer in California, 1988–2000: Racial/Ethnic Variation in 1759 Men

Cynthia O’Malley, Sarah Shema, Edward White, Sally Glaser

Report

Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?

Shailesh Chaturvedi, Catherine McLaren, Andrew C. Schofield, Keith N. Ogston, Tarun K. Sarkar, Andrew W. Hutcheon, Iain D. Miller, Steven D. Heys

Report

Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration

Xihong Zhang, Min Lin, Kenneth L. van Golen, Kiyoko Yoshioka, Kazuyuki Itoh, Douglas Yee

Report

Innate Anti-breast Cancer Immunity of Apoptosis-resistant Human γδ-T cells

Ben L. Guo, Zhiyong Liu, Wayne A. Aldrich, Richard D. Lopez

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine